CRL,PBE Revenue Breakdown

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Dollar change -0.34
Percentage change -0.16	%

Held by: VTI VB VOO VBK IVV RSP IBB VHT IWR SCHM

Index	S&P 500	P/E	25.23	EPS (ttm)	8.61	Insider Own	1.16%	Shs Outstand	51.34M	Perf Week	-1.99%
Market Cap	11.19B	Forward P/E	17.51	EPS next Y	12.40	Insider Trans	-5.10%	Shs Float	50.85M	Perf Month	-4.65%
Income	444.45M	PEG	2.68	EPS next Q	2.39	Inst Own	102.25%	Short Float	3.42%	Perf Quarter	-12.96%
Sales	4.11B	P/S	2.72	EPS this Y	3.35%	Inst Trans	3.21%	Short Ratio	3.32	Perf Half Y	11.42%
Book/sh	70.67	P/B	3.07	EPS next Y	12.47%	ROA	5.61%	Short Interest	1.74M	Perf Year	8.94%
Cash/sh	6.55	P/C	33.16	EPS next 5Y	9.41%	ROE	13.17%	52W Range	161.65 - 275.00	Perf YTD	-8.12%
Dividend Est.	-	P/FCF	27.05	EPS past 5Y	14.84%	ROI	6.61%	52W High	-21.01%	Beta	1.41
Dividend TTM	-	Quick Ratio	1.37	Sales past 5Y	12.89%	Gross Margin	33.16%	52W Low	34.37%	ATR (14)	5.88
Dividend Ex-Date	-	Current Ratio	1.75	EPS Y/Y TTM	-11.13%	Oper. Margin	15.25%	RSI (14)	32.22	Volatility	1.70% 2.46%
Employees	21800	Debt/Eq	0.85	Sales Y/Y TTM	0.49%	Profit Margin	10.81%	Recom	1.94	Target Price	263.40
Option/Short	Yes / Yes	LT Debt/Eq	0.85	EPS Q/Q	-29.82%	Payout	0.00%	Rel Volume	0.60	Prev Close	217.55
Sales Surprise	1.94%	EPS Surprise	9.93%	Sales Q/Q	-1.73%	Earnings	May 09 BMO	Avg Volume	522.58K	Price	217.21
SMA20	-4.99%	SMA50	-10.54%	SMA200	-0.59%	Trades		Volume	312,618	Change	-0.16%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Sep-13-23	Initiated	TD Cowen	Market Perform	$212
Jul-10-23	Downgrade	Citigroup	Buy → Neutral	$260 → $225
Feb-23-23	Upgrade	Guggenheim	Neutral → Buy	$255
Jan-12-23	Downgrade	Jefferies	Buy → Hold
Sep-30-22	Upgrade	Jefferies	Hold → Buy	$240
Aug-25-22	Initiated	Credit Suisse	Outperform	$285
Aug-04-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$350 → $250
May-24-22	Initiated	Guggenheim	Neutral
Apr-25-22	Downgrade	Jefferies	Buy → Hold	$370 → $280
Apr-07-22	Initiated	Stephens	Overweight	$377
Feb-17-22	Upgrade	Citigroup	Neutral → Buy	$400
Feb-17-22	Reiterated	UBS	Buy	$465 → $420
Feb-17-22	Reiterated	Morgan Stanley	Overweight	$465 → $430
Feb-17-22	Reiterated	Deutsche Bank	Buy	$409 → $350
Feb-17-22	Reiterated	BofA Securities	Buy	$445 → $400
Aug-05-21	Resumed	Credit Suisse	Neutral	$385
Dec-16-20	Downgrade	Citigroup	Buy → Neutral	$270 → $250
Sep-10-20	Upgrade	Jefferies	Hold → Buy	$254
Jul-01-20	Upgrade	BofA Securities	Neutral → Buy	$192

Show Previous Ratings

May-24-24 11:38AM	Charles River (CRL) Banks on RMS Growth Amid Competition (Zacks)
May-16-24 08:06PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
May-14-24 07:02PM	Insider Sale: EVP Joseph Laplume Sells Shares of Charles River Laboratories International Inc (CRL) (GuruFocus.com)
May-13-24 12:15PM	Don't Overlook Charles River (CRL) International Revenue Trends While Assessing the Stock (Zacks)
09:40AM	Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term (Zacks)
06:55AM	Loading…
06:55AM	TD Cowen Adjusts Price Target on Charles River Laboratories International to $228 From $260 (MT Newswires)
May-10-24 04:06PM	Charles River Laboratories International, Inc. (NYSE:CRL) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:06AM	JPMorgan Adjusts Price Target on Charles River Laboratories International to $270 From $280 (MT Newswires)
07:22AM	Jefferies Adjusts Price Target on Charles River Laboratories International to $226 From $235 (MT Newswires)
06:14AM	Evercore ISI Adjusts Price Target on Charles River Laboratories International to $265 From $300 (MT Newswires)
06:08AM	Baird Adjusts Price Target on Charles River Laboratories International to $270 From $282 (MT Newswires)
01:03AM	Decoding Charles River Laboratories International Inc (CRL): A Strategic SWOT Insight (GuruFocus.com)
May-09-24 11:22PM	Q1 2024 Charles River Laboratories International Inc Earnings Call (Thomson Reuters StreetEvents)
06:13PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
12:22PM	Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y (Zacks)
11:57AM	Loading…
11:57AM	CRL Stock Earnings: Charles River Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:30AM	Charles River (CRL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:18AM	Charles River beats first-quarter estimates, reaffirms annual forecast (Reuters)
07:49AM	Charles River Laboratories International Q1 Non-GAAP Earnings Rise, Revenue Fall; Maintains Full Year 2024 Earnings Guidance (MT Newswires)
07:34AM	Charles River Laboratories Reaffirms FY24 Outlook; Q1 Results Top Estimates (RTT News)
07:12AM	Charles River: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Charles River Laboratories Announces First-Quarter 2024 Results (Business Wire)
May-08-24 03:29PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
06:00AM	The 7 Best Growth Stocks to Buy in May 2024 (InvestorPlace)
May-06-24 09:15AM	Charles River (CRL) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
May-02-24 08:00AM	Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP (Business Wire)
Apr-24-24 12:47PM	Charles River (CRL) to Report Q1 Earnings: Here's What to Expect (Zacks)
Apr-22-24 08:00AM	Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally (Business Wire)
Apr-18-24 12:09PM	Notice to Long-Term Charles River Laboratories International, Inc. (CRL) Shareholders: Grabar Law Office Is Investigating Claims on Your Behalf (Newsfile)
Apr-16-24 11:50AM	Here's Why You Should Retain Charles River (CRL) Stock Now (Zacks)
08:00AM	Loading…
08:00AM	Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing (Business Wire)
Apr-12-24 08:00AM	Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call (Business Wire)
Apr-11-24 09:10AM	Charles River (CRL) Forges Collaboration With Ship of Theseus (Zacks)
08:00AM	Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology (Business Wire)
Apr-09-24 08:00AM	Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics (Business Wire)
Apr-04-24 08:00AM	Charles River to Perform Plasmid Production for Ship of Theseus (Business Wire)
Apr-01-24 08:00AM	Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024 (Business Wire)
Mar-27-24 08:00AM	Charles River Laboratories Publishes 2023 Corporate Citizenship Report (Business Wire)
Mar-26-24 09:39AM	Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine (Zacks)
Mar-23-24 09:00AM	U.S.-China Decoupling Poses Supply-Chain Risks for Drug Companies (The Wall Street Journal)
Mar-21-24 08:00AM	Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine (Business Wire)
Mar-15-24 11:30AM	Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report? (Zacks)
10:30AM	Charles River (CRL) Extends Gene Therapy Offering With New Pact (Zacks)
Mar-14-24 09:46AM	Here's Why You Should Retain Charles River (CRL) Stock Now (Zacks)
08:00AM	Charles River and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration (Business Wire)
Mar-12-24 08:00AM	Charles River Laboratories to Present at Barclays Global Healthcare Conference (Business Wire)
12:11AM	Insider Sell: CSVP & Chief Accounting Officer Michael Knell Sells Shares of Charles River ... (GuruFocus.com)
Mar-07-24 12:27PM	The Top 3 Healthcare Stocks to Buy in March 2024 (InvestorPlace)
Mar-01-24 11:32PM	Insider Sell: EVP & Chief People Officer Victoria Creamer Sells 5,000 Shares of Charles ... (GuruFocus.com)
Feb-29-24 02:00AM	Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC to Discovery Clients to Accelerate Their Journey to First-in-Human Use (PR Newswire)
Feb-26-24 08:41AM	Charles River (CRL) Forges Collaboration With Wheeler Bio (Zacks)
Feb-21-24 10:40AM	Charles River (CRL) Gains From CRADL Amid Soft Market Scenario (Zacks)
08:00AM	Charles River and Wheeler Bio Complete Agreement to Accelerate the Journey from Discovery and CMC Development to Manufacturing (Business Wire)
Feb-20-24 01:15PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
08:08AM	Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells (Business Wire)
Feb-15-24 01:00PM	The Next Johnson & Johnson? 3 Healthcare Stocks That Investors Shouldnt Ignore. (InvestorPlace)
10:54AM	Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:38AM	Decoding Charles River Laboratories International Inc (CRL): A Strategic SWOT Insight (GuruFocus.com)
Feb-14-24 08:06PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research) +11.30%
09:30AM	Charles River (CRL) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
09:30AM	Charles River (CRL) Q4 Earnings Surpass, Margins Contract (Zacks)
08:09AM	Charles River forecasts strong full-year profit on boost from Noveprim purchase (Reuters)
07:19AM	Charles River: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance (Business Wire)
Feb-13-24 08:20AM	Here's Why You Should Retain Charles River (CRL) Stock Now (Zacks)
Feb-09-24 09:15AM	Unveiling Charles River (CRL) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Feb-01-24 10:08AM	Charles River (CRL) to Report Q4 Earnings: What's in Store? (Zacks)
Jan-29-24 08:00AM	Charles River Introduces the First Rapid Animal-Free Bacterial Endotoxin Test (Business Wire)
Jan-27-24 09:00AM	Big Pharmas great lab monkey shortage: A crackdown on smuggling is causing chaos in Americas vital drug development pipeline (Fortune)
Jan-24-24 04:30PM	Charles River Laboratories Adds Reshema Kemps-Polanco to Board of Directors (Business Wire)
Jan-23-24 04:30PM	Charles River Laboratories Schedules Fourth-Quarter 2023 Earnings and 2024 Guidance Release and Conference Call (Business Wire)
Jan-18-24 09:10AM	Charles River's (CRL) New Launch to Boost Gene Therapy Programs (Zacks)
Jan-16-24 08:00AM	Ten Big Losers To Start The Year. Tesla Isn't The Worst. (Investor's Business Daily)
08:00AM	Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing (Business Wire)
Jan-12-24 02:02PM	Here's Why You Should Retain Charles River (CRL) Stock Now (Zacks)
09:00AM	10 Narrow Moat Stocks Hedge Funds Are Buying (Insider Monkey)
Jan-08-24 08:00AM	Charles River Laboratories to Present at J.P. Morgan Healthcare Conference (Business Wire)
Jan-02-24 09:00AM	How One Texas County Is Fighting 43,000 Monkeys (The Wall Street Journal)
Dec-19-23 08:01AM	Charles River's (CRL) Memphis Site Achieves Crucial Approval (Zacks)
Dec-18-23 08:00AM	Charles River and Vertex Pharmaceuticals Reach Important Milestone in Cell Therapy Manufacturing Collaboration (Business Wire)
Dec-13-23 08:29AM	Charles River (CRL) Expands 3D In Vitro Services Via New Deal (Zacks)
Dec-12-23 08:00AM	Charles River Finalizes Agreement with CELLphenomics, Expanding 3D In Vitro Services for Cancer Therapy Drug Screening (Business Wire)
Dec-08-23 11:30AM	Charles River (CRL) Up 19.7% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-07-23 01:53PM	Investing in the Aging Population: 3 Healthcare Stocks to Watch (InvestorPlace)
Dec-05-23 07:29AM	Here's Why You Should Retain Charles River (CRL) Stock Now (Zacks)
Dec-02-23 01:05AM	Insider Sell: EVP Joseph Laplume Sells Shares of Charles River Laboratories International Inc (CRL) (GuruFocus.com)
Nov-29-23 07:57AM	Charles River (CRL) Backs the Quest to Cure SPG56 via New Deal (Zacks)
Nov-28-23 08:00AM	Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration (Business Wire)
Nov-27-23 08:30AM	Charles River Laboratories to Present at Evercore ISI Investor Conference (Business Wire)
Nov-22-23 03:04AM	Insider Buying: Corporate Executive VP & COO Birgit Girshick Acquires Shares of Charles ... (GuruFocus.com)
Nov-20-23 08:34PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
Nov-17-23 06:45PM	The 3 Most Undervalued Tech Stocks to Buy Now: November 2023 (InvestorPlace)
08:40AM	Charles River (CRL) Widens CliniPrime GMP Suite With New Launch (Zacks)
Nov-16-23 12:59PM	Hedge Fund and Insider Trading News: Ray Dalio, David Einhorn, Ken Griffin, Stanley Druckenmiller, David Tepper, RXO, Inc. (RXO), Charles River Laboratories International (CRL), and More (Insider Monkey)
08:00AM	Charles River Introduces CliniPrime Cryopreserved Leukopaks, Expanding Suite of GMP-Compliant Cellular Products (Business Wire)
Nov-13-23 09:04AM	Charles River and Aitia Enter Strategic Agreement to Utilize Logica in Discovery Programs for Neurodegenerative Diseases and Oncology (PR Newswire)
Nov-10-23 12:11PM	Charles River Laboratories International, Inc. (NYSE:CRL) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 05:14PM	Analyst Report: Charles River Laboratories International, Inc. (Morningstar Research)
08:00AM	Charles River Laboratories Industry Experts to Present Advanced Modalities at Neuroscience 2023 (Business Wire)
01:33AM	Q3 2023 Charles River Laboratories International Inc Earnings Call (Thomson Reuters StreetEvents)

Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The DSA segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MASSARO GEORGE	Director	May 15 '24	Sale	235.62	332	78,225	5,855	May 16 04:35 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	May 10 '24	Sale	226.97	1,304	295,969	23,276	May 14 04:49 PM
Knell Michael Gunnar	CSVP&Chief Accounting Officer	Mar 08 '24	Sale	267.52	808	216,156	7,024	Mar 11 04:42 PM
Knell Michael Gunnar	CSVP&Chief Accounting Officer	Mar 04 '24	Sale	261.05	2,750	717,890	7,832	Mar 05 04:54 PM
Creamer Victoria L	EVP & Chief People Officer	Feb 29 '24	Sale	253.70	5,000	1,268,500	13,550	Mar 01 05:37 PM
Parisotto Shannon M	CEVP, Disc & Safety Assessment	Feb 29 '24	Sale	253.45	3,786	959,545	4,792	Mar 04 04:09 PM
Barbo William D	Corporate Executive VP & CCO	Feb 22 '24	Sale	248.50	4,050	1,006,425	22,879	Feb 23 04:57 PM
Parisotto Shannon M	CEVP, Disc & Safety Assessment	Feb 15 '24	Option Exercise	144.67	5,882	850,949	8,478	Feb 20 05:32 PM
Parisotto Shannon M	CEVP, Disc & Safety Assessment	Feb 15 '24	Sale	241.20	5,882	1,418,767	2,596	Feb 20 05:32 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	Feb 15 '24	Sale	238.93	838	200,223	24,620	Feb 20 05:20 PM
FOSTER JAMES C	Chairman, President and CEO	Jan 29 '24	Option Exercise	144.67	17,436	2,522,466	227,827	Jan 31 04:59 PM
Girshick Birgit	Corporate Executive VP & COO	Jan 10 '24	Option Exercise	215.19	5,916	1,273,064	50,365	Jan 11 04:09 PM
Creamer Victoria L	EVP & Chief People Officer	Dec 14 '23	Option Exercise	136.70	5,526	755,388	22,032	Dec 18 04:07 PM
Creamer Victoria L	EVP & Chief People Officer	Dec 14 '23	Sale	225.00	5,526	1,243,350	16,506	Dec 18 04:07 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	Nov 30 '23	Sale	197.73	1,850	365,800	23,133	Dec 01 04:10 PM
Girshick Birgit	Corporate Executive VP & COO	Nov 20 '23	Buy	187.82	1,322	248,298	44,449	Nov 21 05:07 PM
FOSTER JAMES C	Chairman, President and CEO	Nov 14 '23	Buy	178.05	5,620	1,000,641	202,643	Nov 15 09:23 AM
LaPlume Joseph W	EVP, Corp Strategy & Develop	Nov 09 '23	Option Exercise	144.67	9,128	1,320,548	34,111	Nov 13 04:12 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	Nov 09 '23	Sale	173.48	9,128	1,583,522	24,983	Nov 13 04:12 PM
WALLMAN RICHARD F	Director	Aug 24 '23	Buy	198.79	1,000	198,786	1,000	Aug 29 04:23 PM
Barbo William D	Corporate Executive VP & CCO	Aug 10 '23	Option Exercise	144.67	5,511	797,276	9,103	Aug 14 04:17 PM
Knell Michael Gunnar	CSVP&Chief Accounting Officer	Aug 10 '23	Option Exercise	144.67	1,471	212,810	11,411	Aug 14 04:15 PM
Barbo William D	Corporate Executive VP & CCO	Aug 10 '23	Sale	217.24	5,763	1,251,954	3,592	Aug 14 04:17 PM
Knell Michael Gunnar	CSVP&Chief Accounting Officer	Aug 10 '23	Sale	216.54	1,471	318,530	9,940	Aug 14 04:15 PM
LaPlume Joseph W	EVP, Corp Strategy & Develop	Aug 10 '23	Sale	216.52	700	151,564	24,983	Aug 14 04:11 PM

Dollar change -0.21
Percentage change -0.33	%

Category	US Equities - Industry Sector	Asset Type	Equities (Stocks)	Tags	U.S.	Return% 1Y	2.73%	Shs Outstand		Perf Week	-1.29%
Sponsor	Invesco	ETF Type		Tags	equity	Return% 3Y	-4.12%	Total Holdings	32	Perf Month	6.54%
Fund Family		Bond Type		Tags	biotechnology	Return% 5Y	5.21%	AUM	256.32M	Perf Quarter	-3.23%
Index	Dynamic Biotechnology & Genome Intellide...	Average Maturity		Tags	-	Return% 10Y		NAV%		Perf Half Y	12.43%
Index Weighting		Commodity Type		Tags	-	Return% SI		NAV/sh		Perf Year	2.66%
Active/Passive		Quant Type		Tags	-	Flows% 1M	-0.75%	52W Range	52.47 - 67.76	Perf YTD	-3.16%
Dividend TTM	0.04 (0.06%)	ESG Type		Tags	-	Flows% 3M	-0.26%	52W High	-5.90%	Beta	0.83
Dividend Ex-Date	Mar 18, 2024	Dividend Type		Sector/Theme		Flows% YTD	0.50%	52W Low	21.52%	ATR (14)	0.80
Expense	0.58%	Structure Type		Region		Flows% 1Y		RSI (14)	50.11	Volatility	0.86% 0.95%
Option/Short	Yes / Yes	Growth/Value		Dev/Emerg		Flows% 3Y		Rel Volume	0.94	Prev Close	63.97
Inverse/Leveraged		Market Cap		Currency		Flows% 5Y		Avg Volume	14.93K	Price	63.76
SMA20	-0.02%	SMA50	0.90%	SMA200	3.62%	Trades		Volume	14,064	Change	-0.33%

Aug-18-22 02:00PM	Best Biotech ETFs for Q4 2022 (Investopedia)
Dec-23-20 04:12PM	The hottest ETFs for 2021 (Yahoo Finance Video)
Nov-30-20 08:54AM	2 Biotech Funds Poised for a Healthy Breakout (Investopedia)
Jun-23-20 11:10AM	New GERM ETF Launched to Tap the Growing Biotech Sector (Zacks)
Feb-05-20 06:34AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
07:58AM	Loading…
Jan-13-20 07:58AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
Dec-23-19 12:00PM	Will Biotech ETFs Excel in Election Year Post a Surge in 2019? (Zacks)
Dec-19-19 07:05AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
Dec-02-19 02:40PM	A Guide to Biotech ETF Investing (Zacks)
Nov-27-19 06:52AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
Nov-25-19 06:55PM	Genomics ETFs Surge on CRISPR's Gene Editing Progress (Zacks)
Nov-14-19 01:31PM	Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks (Zacks)
Nov-05-19 08:32AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
Sep-20-19 11:04AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
Sep-06-19 03:07PM	ETFs Poised to Benefit from Gene Editing Revolution (Zacks)
03:18PM	Loading…
Sep-04-19 03:18PM	ETFs to Gain From the Booming Genomics Market (Zacks)
Aug-29-19 07:39AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
Aug-27-19 10:05AM	Amgen to Buy Celgene's Otezla: 5 ETF Drugs (Zacks)
Aug-14-19 08:53AM	3 Charts That Suggest Now Is the Time to Buy Into Biotech (Investopedia)
Aug-07-19 06:45AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
Aug-05-19 12:00PM	7 Biotech ETFs That Should Remain Healthy (InvestorPlace)
Jul-16-19 07:01AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
Jun-21-19 09:15AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
Jun-18-19 09:55AM	Pfizer-Array Biopharma Deal Bump Up Biotech ETFs (Zacks)
May-30-19 06:53AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
May-10-19 01:00PM	Top and Flop ETFs So Far in Q2 (Zacks)
May-08-19 08:03AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
Apr-12-19 07:23AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
Apr-10-19 04:44PM	Global X Launches GNOM ETF to Tap Booming Genomics Space (Zacks)
Mar-20-19 07:07AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
11:15AM	Loading…
Feb-26-19 11:15AM	Biotech ETFs Jump on Roche-Spark Deal (Zacks)
Feb-25-19 01:59PM	Spark Therapeutics Acquisition Sparks Rally in Biotechnology ETFs (ETF Trends) +5.31%
Feb-20-19 09:32AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
Dec-13-18 07:32AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
Nov-21-18 09:47AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
Nov-20-18 02:03PM	7 Biotech ETFs to Consider for 2019 (InvestorPlace)
Oct-30-18 08:08AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
Oct-08-18 08:25AM	Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? (Zacks)
Jul-31-18 03:52PM	Biotech ETFs Rally as Illumina Tops Q2 Expectations (ETF Trends)
Apr-12-18 07:19AM	Is PowerShares Dynamic Biotechnology & Genome Portfolio (PBE) a Hot ETF Right Now? (Zacks)
Jan-10-18 04:10PM	Exploring Ioniss 3Q17 Quarterly Revenue Trend (Market Realist)
Sep-21-17 02:13PM	Gene-Editing Could Modify and Cure Disease: CRISPR vs. TALENs (Harvest Exchange)
11:56AM	A Shot in the Arm for the UK Life Sciences Industry? (Harvest Exchange)
Sep-12-17 09:06AM	How Did Gileads Blockbuster Drug Harvoni Perform in 2Q17? (Market Realist)
Aug-23-17 04:18PM	Whats Ionis Pharmaceuticals Valuation? (Market Realist)
Jul-10-17 02:35PM	What Drove Biogen Stock in 2Q17? (Market Realist)
Jun-14-17 03:04PM	How Incytes Valuation Has Changed since 1Q17 Results (Market Realist)
Jun-09-17 04:47PM	Changes in Ionis Pharmaceuticals Valuation after 1Q17 (Market Realist)
May-05-17 05:16PM	ETF Flopper: Biotech Bungle (Barrons.com)
Mar-13-17 05:46PM	Time to Buy Biotech ETFs?
05:46PM	Time to Buy Biotech ETF? (Zacks)
Mar-02-17 02:00PM	Trump's Immigration Plans an Overhang on Biotech ETFs? (Zacks)
Mar-01-17 09:06AM	A Look at Incytes Product Portfolio (Market Realist)
Jan-27-17 04:30PM	What Lies Ahead for Biotech ETFs in Trump Era? (Zacks)
Jan-12-17 10:08AM	Trump Attacks Biotech & Pharma: ETFs Bleed (Zacks)
Jan-09-17 07:36AM	Whats in Incytes Product Portfolio? (Market Realist)
Dec-15-16 01:04PM	POWERSHARES EXCHANGE TRADED FUND TRUST Financials
Dec-02-16 10:04AM	Neurocrine Biosciences Pursues Womens Health Segment with Elagolix (Market Realist)
Nov-08-16 03:26PM	Biotech ETFs Slumping on Q3 Results (Zacks)
Oct-27-16 12:19PM	4 Frightful ETFs of This Year (Zacks)
Oct-11-16 08:04AM	How Did Gileads Other Products Perform in 2Q16?
Oct-07-16 01:16PM	Is the Dividend ETF Bull Run Over?
Oct-05-16 09:42AM	3 ETFs to Buy for a Media Merger Frenzy
Sep-01-16 11:04AM	How Are Eli Lillys Business Segments Performing?
Aug-31-16 03:39PM	Biotech ETF Industry Outlook
Aug-24-16 10:04AM	Why Did Hormel Foods Increase Its Fiscal 2016 Guidance?
Aug-23-16 09:30AM	The Zacks Analyst Blog Highlights: PureFunds ISE Junior Silver ETF, SPDR S&P Technology Hardware ETF, PowerShares Dynamic Semiconductors ETF, SPDR S&P Health Care Services ETF and PowerShares DWA Utilities Momentum ETF
Aug-04-16 09:47AM	Top Tech ETFs Of 2016
Jul-27-16 11:57AM	This Seasonal ETF Is Ripe For The Pickin' This Summer
Jul-25-16 09:20AM	A Consumer Staples ETF To Feast On
Jul-23-16 12:00PM	Restaurants Reflect Consumption Trends (Literally)
Jul-12-16 05:05PM	Why Are So Many Analysts Rating B&G Foods a Hold?
Jul-11-16 10:05AM	Why Did BioMarins Share Price Tank after Brexit?
Jul-05-16 10:53AM	Top and Flop Sector ETFs YTD
Jun-29-16 05:09PM	Inside Neurocrine Biosciences Analyst Recommendations in 2016
10:59AM	Why Did Cal-Maine Shares Fall 23% in the Last 3 Months?
Jun-10-16 09:06AM	An Inside Look at Incytes Product Portfolio
May-13-16 04:48PM	What Lies Ahead for Biotech ETFs?
May-11-16 06:05AM	Hain Celestial Traded above Key Moving Averages
May-04-16 09:00AM	Finding Pharmaceuticals ETFs With Rebound Potential
Apr-07-16 04:04PM	How Does Incytes Valuation Compare to Peers?
Mar-18-16 08:20AM	Potent Value In This Large-Cap ETF
Mar-09-16 06:37AM	5 Best Performing Bull Run Equity ETFs
Mar-01-16 11:27PM	Worst Performing ETFs Of 2016 To Date
Jan-22-16 09:31AM	2 ETFs That Surged to Rank #1 Braving All Odds
Jan-21-16 06:18PM	Consumer Discretionary ETFs Rise But Starbucks Cools (Investor's Business Daily)
Jan-13-16 12:09PM	Why Did the US Halt Bunges Canola Meal Shipment? -6.11%
Jan-11-16 01:38PM	An ETF For Growth With A Broad Supporting Cast
Jan-08-16 02:10PM	Deutsche Bank Downgrades Mondelz International
Jan-05-16 07:49PM	Pharmaceutical ETFs Perk Up As Stock Market Stays Skittish (Investor's Business Daily)
Jan-04-16 08:38AM	Head To The Polls With This ETF In 2016
Dec-24-15 04:48PM	How Does Cal-Maine Foods Compare to Its Peers?
09:59AM	Meet This Year's Best Industrial ETF
Dec-21-15 12:22PM	Top 10 Smart Beta ETFs Of 2015
Dec-08-15 08:20AM	How Did Marvell Technology Group Compare to Its Peers? (Market Realist)
Dec-03-15 10:29AM	How Does American Eagle Outfitters Compare to Its Peers?
08:02AM	How Does Synopsys Compare to Its Peers?
Dec-01-15 10:07AM	A Fund Flow and Volume Analysis of ICF and PJP
Nov-30-15 01:38PM	A Structural Analysis of Smart Beta Fund ICF
Nov-23-15 08:24PM	Pharma ETFs Pop Amid Pfizer-Allergan $160 Bil Deal (Investor's Business Daily)

Invesco Dynamic Biotechnology & Genome ETF seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

open in screener | open in yahoo | open in marketwatch | open in google

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

CRL

Charles River Laboratories International Inc.

PBE

Invesco Biotechnology & Genome ETF

CRL

Charles River Laboratories International Inc.

PBE

Invesco Biotechnology & Genome ETF

Upgrade your FINVIZ experience